Booklet Provides Guidance on Appointing or Being a Health Care Proxy

Publication
Article
OncologyONCOLOGY Vol 12 No 12
Volume 12
Issue 12

Choice In Dying (Washington, DC) recently released a new booklet entitled, “Healthcare Agents: Appointing and Being One,” intended to serve as a reference when appointing a health care agent (proxy) or acting as one.

Choice In Dying (Washington, DC) recently released a new booklet entitled, “Healthcare Agents: Appointing and Being One,” intended to serve as a reference when appointing a health care agent (proxy) or acting as one. Providing answers to common questions and highlighting difficult topics everyone should consider, the new booklet helps individuals select agents who will be successful advocates and also helps reduce agents’ uncertainty over which decisions best reflect the patients’ wishes.

Among other important issues, the booklet urges people to talk with family members and agents about medical treatment decisions and personal values as a way to ensure that their dignity and quality of life will be respected. People should not assume that their closest relatives would automatically want to be agents or will know their wishes, the booklet warns.

The thoughtful appointment of a health care agent is one of the best ways to ensure that end-of-life medical care decisions are heard, understood, and honored. “Instead of seeing end-of-life decisions as a blank canvas on which others will paint, put the paint brush in your own hands. Appoint a proxy and paint a picture of the life you want to live up to the last minute. Protect your choices and at the same time protect your family from the emotional anguish and conflict of not knowing your wishes. That is the best gift you can give them,” said Dr. Karen Kaplan, executive director of Choice In Dying.

Recent Videos
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video
Related Content